Dipankar Das

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Raches Ella, Siddharth Reddy, Harsh Jogdand et al. · The Lancet Infectious Diseases · 2021 · 360 citations · Full text

The toxicity of antiprion antibodies is mediated by the flexible tail of the prion protein

Tiziana Sonati, Regina Reimann, Jeppe Falsig et al. · Nature · 2013 · 206 citations

Protein Function, Protein Folding, Flexible Tail +10

Synthesis of Celecoxib Analogues Possessing a<i>N</i>-Difluoromethyl-1,2-dihydropyrid-2-one 5-Lipoxygenase Pharmacophore: Biological Evaluation as Dual Inhibitors of Cyclooxygenases and 5-Lipoxygenase with Anti-Inflammatory Activity

Morshed Alam Chowdhury, Khaled R.A. Abdellatif, Ying Dong et al. · Journal of Medicinal Chemistry · 2009 · 178 citations · Full text

Dendritic Cell Targeted Chitosan Nanoparticles for Nasal DNA Immunization against SARS CoV Nucleocapsid Protein

Dharmendra Raghuwanshi, Vivek Mishra, Dipankar Das et al. · Molecular Pharmaceutics · 2012 · 121 citations · Full text

Nanoparticles, Engineering, Immunology +16

Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation

Brunda Ganneru, Harsh Jogdand, Vijaya Kumar Daram et al. · iScience · 2021 · 92 citations · Full text